<DOC>
	<DOC>NCT01952015</DOC>
	<brief_summary>The purpose of this study is to assess efficacy and safety data of secukinumab in Japanese subjects with generalized pustular psoriasis (GPP). This study is expected to support the filing of secukinumab in the indication of pustular psoriasis in Japan.</brief_summary>
	<brief_title>Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>At baseline, presence of GPP classified on the basis of the criteria for diagnosis of GPP by Japanese Dermatological Association (JDA) At baseline, erythema area with pustule ≥ 10% Erythrodermic, guttate psoriasis, or subcorneal pustular dermatosis at screening. At baseline, : total score of JDA severity index for GPP ≥ 14 Druginduced psoriasis Ongoing use of prohibited psoriasis treatments. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>generalized pustular psoriasis</keyword>
</DOC>